Current filters:  
United States
Crowell & Moring LLP
On Monday, February 5, 2024, the Federal Circuit held its first en banc oral argument on a patent case in five years.
Mayer Brown
In accordance with an executive order on the use of artificial intelligence ("AI"), the United States Patent and Trademark Office ("USPTO") published guidance on February 13, 2024...
Wolf, Greenfield & Sacks, P.C.
Scott McKeown is a shareholder in Wolf Greenfield's Post-Grant Proceedings Practice. Based in the firm's Washington, DC office, Scott focuses his practice on high-stakes...
Axinn Veltrop & Harkrider
According to Judge Gilstrap in the Eastern District of Texas, obligations to negotiate under fair, reasonable, and non-discriminatory (FRAND)...
Foley Hoag LLP
On February 13, 2024, the USPTO (PTO) published its guidance for inventions made with the assistance of artificial intelligence (AI).
Duane Morris LLP
The Federal Trade Commission (FTC) has announced its support of the federal government's use of "march-in rights" as a mechanism to control the price of pharmaceuticals.
Oblon, McClelland, Maier & Neustadt, L.L.P
The Federal Circuit on February 9 decided another written description case involving a range not found in ipsis verbis in the patent specification in RAI Strategic Holdings Inc. v. Philip...
Jones Day
USPTO Director Katherine K. Vidal issued guidance on February 6, 2024 regarding the use of AI in drafting materials submitted to the USPTO's administrative boards, including the PTAB.
Oblon, McClelland, Maier & Neustadt, L.L.P
The Patent Trial and Appeal Board (PTAB) recently reversed the novelty, obviousness, and obviousness-type double patenting (ODP) rejections of the examining corps in a Track One case...
Polsinelli LLP
On February 6, 2024, the Federal Trade Commission ("FTC") commented in support of what would be a historic expansion of government march-in rights under the Bayh-Dole Act...
Foley & Lardner
U.S. Patent and Trademark Office (USPTO) Director Kathi Vidal recently released a memorandum on the subject of the use of artificial intelligence (AI)...
Jones Day
While it is well-established under U.S. law that a patent inventor must be a human being, there has been substantial uncertainty as to the patentability of inventions made with the assistance of AI.
Axinn Veltrop & Harkrider
Judge Bryson's recent decision sitting by designation in Prolitec Inc. v. Scentair Technologies, LLC., No. 20-984-WCB, 2024 WL 341342 (D. Del. Jan. 30, 2024)...
Holland & Knight
The U.S. Patent and Trademark Office (USPTO) issued new guidance on Feb. 12, 2024, regarding the use of artificial intelligence (AI) while developing new inventions.
Novagraaf Group
Depuis le 17 janvier 2024, l'USPTO exige une surtaxe de 400$ pour tout dépôt de demande de brevet autrement qu'en format ‘DOCX'.
Harness IP
The USPTO released inventorship guidance on February 12, 2024, for inventions assisted by artificial intelligence (AI).
Crowell & Moring LLP
The United States Patent and Trademark Office (USPTO) issued a Federal Register Notice on February 13, 2024 explaining how it will analyze patent inventorship issues for inventions...
Foley & Lardner
The U.S. Patent and Trademark Office (USPTO) has released new training materials on "Declaration practice under 37 CFR 1.132 (Rule 132)."
Buchanan Ingersoll & Rooney PC
As Artificial Intelligence (AI) continues to develop, it is increasingly being used to aid in developing new products and processes.
Axinn Veltrop & Harkrider
Bayer's ‘053 patent on its drug Xarelto® expires in November 2024, and Bayer granted Mylan a covenant not to sue. Bayer has a second patent that is subject to a pediatric exclusivity that expires later.
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Popular Contributors
Upcoming Events
Mondaq Social Media